Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Deferred Revenue: 2024-2025

Historic Current Deferred Revenue for Day One Biopharmaceuticals (DAWN) over the last 1 years, with Sep 2025 value amounting to $2.3 million.

  • Day One Biopharmaceuticals' Current Deferred Revenue rose 58.48% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 58.48%. This contributed to the annual value of $1.6 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Current Deferred Revenue stood at $2.3 million, which was up 25.45% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Current Deferred Revenue registered a high of $2.3 million during Q3 2025, and its lowest value of $1.5 million during Q3 2024.
  • For the 2-year period, Day One Biopharmaceuticals' Current Deferred Revenue averaged around $1.8 million, with its median value being $1.6 million (2025).
  • Data for Day One Biopharmaceuticals' Current Deferred Revenue shows a peak YoY surged of 58.48% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Day One Biopharmaceuticals' Current Deferred Revenue stood at $1.6 million in 2024, then soared by 58.48% to $2.3 million in 2025.
  • Its Current Deferred Revenue was $2.3 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.6 million in Q1 2025.